Anavex Life Sciences Corp (AVXL)

[WilliamMunny]

Actually, Talon, Biogen is holding below $200 because of - not despite - Leqembi. The drug is falling well below sales projections. There are a variety of reasons, of course: physicians are, not surprisingly, quite leery about the possible side effects from a drug that is the first one with a black-box warning to be granted full approval by the FDA in two decades; infusion center capacities also seem to be a problem; getting PET scans signed off by private Medicare Advantage plans is another issue; approval by the EMA has been held up for further review, since the previously cited issues would seem to be even more of a problem in Europe; and Biogen/Eisai have been forced to delay an application for an injectable version after the FDA asked for several more months of immune response data. So, yes, Leqembi is doing no favors for BIIB shareholders.